|
CNS Cluster Addiction Drug Development Pipeline Review, 2017 |
May 8 2017 |
150 |
Global |
$3,995.00 |
|
|
Diabetes and Associated Metabolic Conditions Drug Development Pipeline Review, 2018 |
Jun 29 2018 |
344 |
Global |
$3,995.00 |
|
|
Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression |
May 1 2017 |
101 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis |
Aug 1 2017 |
113 |
Global |
$6,995.00 |
|
|
Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline |
May 3 2017 |
84 |
Global |
$6,995.00 |
|
|
Frontier Pharma: Transplantation Therapeutics - A Highly Innovative Pipeline with a Range of Adaptive and Innate Immune-Targeting Programs Focusing on Graft-Versus-Host Disease and Kidney Transplantation |
Dec 1 2017 |
72 |
Global |
$6,995.00 |
|
|
Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Review, 2017 |
May 8 2017 |
79 |
Global |
$3,995.00 |
|
|
Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth |
May 1 2017 |
140 |
Global |
$4,995.00 |
|
|
Hepatitis Drug Development Pipeline Review, 2017 |
Aug 1 2017 |
209 |
Global |
$3,995.00 |
|
|
Hepatitis Drug Development Pipeline Review, 2018 |
Jun 29 2018 |
133 |
Global |
$3,995.00 |
|
|
Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs |
May 1 2016 |
60 |
Global |
$2,995.00 |
|
|
Influenza A Viral Infections Drug Development Pipeline Review, 2018 |
Apr 30 2018 |
188 |
Global |
$3,995.00 |
|
|
Menopausal Disorders Drug Development Pipeline Review, 2018 |
Jun 29 2018 |
84 |
Global |
$3,995.00 |
|
|
Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 |
Aug 1 2017 |
254 |
Global |
$3,995.00 |
|
|
Pain Drug Development Pipeline Review, 2017 |
Jul 1 2017 |
229 |
Global |
$3,995.00 |
|
|
Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market |
Jun 1 2018 |
125 |
Asia Pacific |
$4,995.00 |
|
|
Renal Cluster Drug Development Pipeline Review, 2017 |
May 11 2017 |
181 |
Global |
$3,995.00 |
|
|
Skeletal Disease Drug Development Pipeline Review, 2017 |
Jul 1 2017 |
176 |
Global |
$3,995.00 |
|
|
Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 |
May 9 2017 |
139 |
Global |
$3,995.00 |
|
|
Transplantation Drug Development Pipeline Review, 2017 |
Jul 1 2017 |
242 |
Global |
$3,995.00 |
|
|
Women's Health Cluster Drug Development Pipeline Review, 2017 |
May 10 2017 |
123 |
Global |
$3,995.00 |
|
